Drug Profile
Dusigitumab - AstraZeneca
Alternative Names: MEDI-573Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Insulin-like growth factor I inhibitors; Insulin-like growth factor II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Liver cancer; Solid tumours
Most Recent Events
- 28 Jun 2019 MedImmune completes a phase Ib/II trial for Breast cancer (Combination therapy, Metastatic disease) in USA, Canada, Bahamas, United Kingdom, Belgium, France, Germany, Hungary, Poland, Spain & Israel (IV) (NCT01446159)
- 09 Feb 2018 Discontinued - Phase-I for Solid tumours (Late-stage disease) in Japan (IV) due to safety and efficacy issues before February 2018 (MedImmune pipeline, February 2018)
- 09 Feb 2018 Discontinued - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV) due to safety and efficacy issues before February 2018 (MedImmune pipeline, February 2018)